Expression and clinical significance of the phosphatidylinositol 3-kinase/protein kinase B signal transduction pathway in non-small cell lung carcinoma

Oncology Letters

Volumn 8, Issue 2, 2014, Pages 601-607

  Jiang, Ai Gui ^a   Yu, Hong ^a   Huang, Jian An ^b  

^a TAIZHOU PEOPLE S HOSPITAL   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Non small cell lung carcinoma; Phosphatidylinositol 3 kinase; Prognosis; Protein kinase B

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER STAGING; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

EID: 84902347892     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2167     Document Type: Article

References (25)

1. Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83: 584-594, 2008.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
3. Cantrell DA: Phosphoinositide 3-kinase signaling pathways. J Cell Sci 114: 1439-1445, 2001.
4. Hennessy BT, Smith DL, Ram PT, Lu Y and Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4: 988-1004, 2005.
5. Sunayama J, Sato A, Matsuda K, et al: Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells. Neuro Oncol 12: 1205-1219, 2010.
6. Zhou J, Wulfkuhle J, Zhang H, et al: Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci USA 104: 16158-16163, 2007.
7. Missiaglia E, Dalai I, Barbi S, et al: Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 28: 245-255, 2010.
8. Al-Saad S, Donnem T, Al-Shibli K, Persson M, Bremnes RM and Busund LT: Diverse prognostic roles of AKT isoforms, PTEN and PI3K in tumor epithelial cells and stromal compartment in non-small cell lung cancer. Anticancer Res 29: 4175-4183, 2009.
9. David O, Jett J, LeBeau H, et al: Phospho-Akt over expression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res 10: 6865-6871, 2004.
10. Tang JM, He QY, Guo RX and Chang XJ: Phosphorylated Akt over expression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 51: 181-191, 2006.
11. Tsao AS, McDonnell T, Lam S, et al: Increased phospho-AKT (Ser (473) expression in bronchial dysplasia: implications for lung cancer prevention studies. Cancer Epidemiol Biomarkers Prev 12: 660-664, 2003.
12. Tsurutani J, Fukuoka J, Tsurutani H, et al: Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small cell lung cancer tumors. J Clin Oncol 24: 306-314, 2006.
13. Shah A, Swain WA, Richardson D, et al: Phospho-Akt expression is associated with a favorable outcome in non-small cell lung cancer. Clin Cancer Res 11: 2930-2936, 2005.
14. Groome PA, Bolejack V, Crowley JJ, et al: IASLC International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions: The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumors. J Thorac Oncol 2: 694-705, 2007.
15. Shaw RJ and Cantley LC: Ras, PI(3)K and mTOR signalling controls tumor cell growth. Nature 441: 424-430, 2006.
16. Pisick E, Jagadeesh S and Salgia R: Receptor tyrosine kinases and inhibitors in lung cancer. ScientificWorldJournal 4: 589-604, 2004.
17. Brunet A, Bonni A, Zigmond MJ, et al: Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868, 1999.
18. Henshall DC, Araki T, Schindler CK, et al: Activation of bcl-2 associated death protein and counter-response of Akt within cell populations during seizure-induced neuronal death. J Neurosci 22: 8458-8465, 2002.
19. Duguay D and deBlois D: Differential regulation of Akt, caspases and MAP kinases underlies smooth muscle cell apoptosis during aortic remodelling in SHR treated with amlodipine. Br J Pharmacol 151: 1315-1323, 2007.
20. Diehl JA, Cheng M, Roussel MF and Sherr CJ: Glycogen synthase kinase-3b regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12: 3499-3511, 1998.
21. Sunters A, Madureira PA, Pomeranz KM, Aubert M, Brosens JJ, Cook SJ, et al: Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt. Cancer Res 66: 212-220, 2006.
22. Wang L, Cao XX, Chen Q, Zhu TF, Zhu HG and Zheng L: DIXDC1 targets p21 and cyclin D1 via PI3K pathway activation to promote colon cancer cell proliferation. Cancer Sci 100: 1801-1808, 2009.
23. Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N and Hay N: Akt activates mTOR by regulating cellular ATP and AMPK activity. J Biol Chem 280: 32081-32089, 2005.
24. Zhang R, Xu Y, Ekman N, et al: Etk/Bmx transactivates vascular endothelial growth factor 2 and recruits phosphatidylinositol 3-kinase to mediate the tumor necrosis factor-induced angiogenic pathway. J Biol Chem 278: 51267-51276, 2003.
25. Balsara BR, Pei J, Mitsuuchi Y, et al: Frequent activation of Akt in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 25: 2053-2059, 2004.